All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies

Contact the Supplier

Lead Product(s): Wnt Activating Antibodies

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Surrozen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 29, 2020

Details:

Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.

Versameb

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials

Contact the Supplier

Lead Product(s): RNA based therapies

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $6.3 million Upfront Cash: Undisclosed

Deal Type: Financing July 15, 2020

Details:

Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.